# **ACG 2024**



# Research Highlights Opportunity for Machine Learning (ML) to Address Shortcomings in GI Endoscopic Assessments

Five abstracts presented at ACG from key members in the GI scientific community showcasing the promise of machine learning (ML) models to advance GI clinical research, address unmet patient needs, and lay the foundation for future innovation in drug development and endpoint assessment

## Challenges in Endoscopy

#### Opportunities to Advance Endoscopic Assessment of IBD



**Trial efficacy** demonstrated by endoscopic effect size in trials<sup>2</sup> and notable differences in endoscopic treatment effect between phase 2 and phase 3 trials for investigational new drugs<sup>3</sup>

## **Opportunity**

# Promise of machine learning (ML) enabled disease assessments



**Rapidly assess disease activity** in a quantitative, unbiased manner



**Inform novel, advanced insights** on disease activity

"Our ongoing research with Iterative Health shows the immense potential of their machine learning tools to refine endoscopic assessments and thereby enhance the drug development process, ultimately improving long-term patient outcomes."



David T. Rubin, MD

Director of the Inflammatory Bowel Disease
Center at the University of Chicago Medicine

#### **Real World Evidence**

#### **Topics**

- Retrospective analysis
- Al-endoscopic video analysis paired with EHR data

#### **Research Goal**

 Real-world evidence generating novel insights on endoscopic assessments impact on treatment selection for targeted IBD therapies to improve understanding of clinical care in a diverse community setting

# **Clinical Insights**

#### **Topics**

- 4 abstracts
- Evaluation of root-causes of variability in human assessments
- Head-to-Head Evaluation of multiple ML models
- Systematic Review and recommendations

#### **Research Goal**

 Advance the science of machine learning assessments of endoscopy in ulcerative colitis (UC) and the it's impact on clinical trials

## Impact to GI Scientific Community

Iterative Health's recently publications showcase our ongoing partnerships with renowned researches and leading life science organizations to transform traditional endpoints to provide advanced, actionable insights and shift the paradigm in evidence generation for GI diseases

# Scientific Publications Presented at ACG 2024

# **Clinical Insights**

Machine Learning Assessments of the Endoscopic Mayo Score in Ulcerative Colitis: A Systematic Review on Testing of Video-Level Assessment Models

#### **Authors:**

David Rubin, Walter Reinisch, Neeraj Narula, Daniel Colucci, William Eastman, Klaus Gottlieb, Ana Lacerda, Stephen Laroux, Irene Modesto, Emma Navajas, Charles Owens, Yeli Wang, Shrujal Baxi

## Methodology:

Systematic review

# Academic & Clinical Partners:

University of Chicago University of Vienna McMaster University Life Science Partners:

Eli Lilly, AbbVie, Pfizer

#### **Key Findings:**

Five studies reporting data from six unique test cohorts showcased accuracy in predicting ordinal eMS grades (0, 1, 2, 3) ranging from 56.8-83.3%

Machine Learning Assessments of the Endoscopic Mayo Score in Ulcerative Colitis: A Systematic Review on Training of Video-Level Assessment Models

#### **Authors:**

David Rubin, Walter Reinisch, Neeraj Narula, Daniel Colucci, William Eastman, Klaus Gottlieb, Ana Lacerda, Stephen Laroux, Irene Modesto, Emma Navajas, Charles Owens, Yeli Wang, Shrujal

# Methodology:

Systematic review

# Academic & Clinical Partners:

University of Chicago University of Vienna McMaster University Life Science Partners:

Eli Lilly, AbbVie, Pfizer

## **Key Findings:**

Seven studies outlined ML training to predict endoscopic scores in ulcerative colitis (UC) with varying model architecture and data labeling strategies

#### PRESIDENTIAL POSTER AWARD WINNER

Head-to-Head Evaluation of Two Machine Learning Algorithms for Predicting Endoscopic Mayo Score in Ulcerative Colitis

#### **Authors:**

Chakib Battioui, Pavel Brodskiy, Klaus Gottlieb, Mohammad Haft-Javaherian, Evan Yu, Shrujal Baxi (lead/sr investigator)

#### Methodology:

Head-to-head product evaluation

## Life Science Partners:

Eli Lilly

## **Key Findings:**

Machine learning models developed by Iterative Health accurately assess endoscopic response (81 -88%) and remission (92 - 96%)

### The Role of Video Quality in Central Reader Disagreement in Assessment of the **Endoscopic Mayo Score in Ulcerative Colitis Trials**

#### **Authors:**

Edward V. Loftus, Jr., David T. Rubin, Nayantara Coelho-Prabhu, Walter Reinisch, Chakib Battioui, Abbey Brinkey, Daniel Colucci, William Eastman, Hannah Thompson, Yeli Wang, Shrujal Baxi

## Methodology:

Life Science Partners: Retrospective analysis Eli Lilly

#### **Key Findings:**

Concluded association with poor quality of bowel preparation with disagreement in endoscopic assessments

# Real World Evidence

Investigating the Relationship Between Endoscopic Characteristics and Treatment Choice for Patients with Ulcerative Colitis Using a Real-world Data Set Linked to **Endoscopic Videos Evaluated with Computer Vision** 

#### **Authors:**

Shrujal Baxi,P arambir S Dulai, Ronen Arai, Darren Thomason, Megan Gower, Maggie McCue, Chris Blair, Lisa Young, Vijay Yajnik

#### Methodology:

Retrospective analysis

# Academic & **Clinical Partners:**

University of Chicago University of Vienna **McMaster University** 

## Life Science **Partners:**

Eli Lilly, AbbVie, Pfizer

## **Key Findings:**

Five studies reporting data from six unique test cohorts showcased accuracy in predicting ordinal eMS grades (0, 1, 2, 3) ranging from 56.8-83.3%

"The goal of our partnership with Iterative Health is to facilitate more evidence-based decision-making on therapy utilization in the real world, and ultimately get a step closer to precision medicine in IBD."




Dr. Vijay Yajnik

Vice President, Head of Gastroenterology, US Medical Affairs, Takeda

# **Technology and Services Empowering** Research

Data & Insights is a technology and service offering from Iterative Health leveraging advanced AI capabilities and multimodal research data to generate novel insights that inform optimal clinical development and post-marketing strategies







# Let's Partner



Interested in joining our scientific roadmap or learning more on our technology? Get in touch with the Data & Insights team.



#### **About Iterative Health**

Iterative Health is a healthcare technology & services company on a mission to provide timely access to a higher standard of gastroenterology care. With deep expertise in artificial intelligence and clinical research, we're empowering healthcare professionals to provide consistently high-quality colorectal cancer screenings and supporting clinical research teams and study sponsors to expand and accelerate patient access to novel therapeutics.

<sup>3.</sup> Wils P, Jairath V, Sands BE, Magro F, Reinisch W, Rubin D, et al. Comparison of treatment effect between phase 2 and phase 3 trials in patients with inflammatory bowel disease. United Eur Gastroenterol J. 2023 Oct;11(8):797–806.



<sup>1.</sup> Hashash JG, Yu Ci Ng F, Farraye FA, Wang Y, Colucci DR, Baxi S, et al. Inter- and Intraobserver Variability on Endoscopic Scoring Systems in Crohn's Disease and Ulcerative Colitis:

A Systematic Review and Meta-Analysis. Inflamm Bowel Dis. 2024 Mar 28;izae051.

2. Reinisch W, Pradhan V, Ahmad S, Zhang Z, Gale JD. Alternative Endoscopy Reading Paradigms Determine Score Reliability and Effect Size in Ulcerative Colitis. J Crohns Colitis.